Back to Search Start Over

Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement.

Authors :
Mangione CM
Barry MJ
Nicholson WK
Cabana M
Caughey AB
Chelmow D
Coker TR
Davis EM
Donahue KE
Jaén CR
Kubik M
Li L
Ogedegbe G
Pbert L
Ruiz JM
Stevermer J
Wong JB
Source :
JAMA [JAMA] 2022 Nov 01; Vol. 328 (17), pp. 1740-1746.
Publication Year :
2022

Abstract

Importance: Menopause is defined as the cessation of a person's menstrual cycle. It is defined retrospectively, 12 months after the final menstrual period. Perimenopause, or the menopausal transition, is the few-year time period preceding a person's final menstrual period and is characterized by increasing menstrual cycle length variability and periods of amenorrhea, and often symptoms such as vasomotor dysfunction. The prevalence and incidence of most chronic diseases (eg, cardiovascular disease, cancer, osteoporosis, and fracture) increase with age, and US persons who reach menopause are expected on average to live more than another 30 years.<br />Objective: To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal persons and whether outcomes vary by age or by timing of intervention after menopause.<br />Population: Asymptomatic postmenopausal persons who are considering hormone therapy for the primary prevention of chronic medical conditions.<br />Evidence Assessment: The USPSTF concludes with moderate certainty that the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons with an intact uterus has no net benefit. The USPSTF concludes with moderate certainty that the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy has no net benefit.<br />Recommendation: The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy. (D recommendation).

Details

Language :
English
ISSN :
1538-3598
Volume :
328
Issue :
17
Database :
MEDLINE
Journal :
JAMA
Publication Type :
Academic Journal
Accession number :
36318127
Full Text :
https://doi.org/10.1001/jama.2022.18625